EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases

Sodai Yoshimura, Takashi Ohta, Kotaro Makita, Shun Yamamuro, Yushi Ochai, Koichiro Sumi, Katsunori Shijo, Atsuo Yoshino, Taku Homma, Masahiko Sugitani, Sayaka Yuzawa, Hiroshi Nishihara, Sinya Tanaka

Research output: Contribution to journalArticle

Abstract

Background: Anaplastic meningioma is exceedingly rare, and its clinicopathological features are distinctive. Distant meningioma metastases have previously been reported to be very rare. The most common site of metastasis is the lung, which accounts for 61% of all meningioma metastases. The standard therapy for meningiomas is total resection and/or radiation therapy. Case Report: A 71-year-old man was admitted with headache and left hemiparesis. Magnetic resonance imaging (MRI) revealed mass lesions at the right frontal convexity and left occipital lobe. Following surgery, pathological examinations demonstrated an anaplastic meningioma. At 3 months after the operation and radiation therapy, lung tumor was removed. The pathological findings for the lung tumor resembled those of the brain tumor. A diagnosis of metastatic lung tumor from anaplastic meningioma was made. At 2 months after the lung surgery, MRI disclosed focal recurrence in the frontal convexity area and progression into the cavernous sinus. Abdominal CT detected a new metastatic lesion in the patient’s liver. He underwent adjuvant reirradiation consisting of whole brain radiotherapy. In addition, he received chemotherapy using angiogenesis receptor (bevacizumab). Chemotherapy with hydroxyurea was initiated after 2 courses of the bevacizumab chemotherapy, because his hepatic lesion had become more aggressive. The intracranial mass was reduced by 50% at 8 weeks after initiation of the hydroxyurea chemotherapy. However, there was no significant effect on the liver and lung metastases. Analysis and Conclusion: Extracranial metastases have been estimated to occur in only 0.1% of all meningiomas and most often in association with anaplastic meningiomas. While total resection and/ or radiation treatment provide the standard therapy for meningiomas, use of chemotherapy against meningiomas has been limited to distant metastases or based on out of surgical criteria. Several reports have demonstrated that hydroxyurea provides on effective chemotherapy for meningiomas including grade I cases. Hydroxyurea halts meningioma cell growth through arrest of the S-phase of the cell cycle, thus inducing apoptosis. Our analysis revealed EXO1 homozygous deletion at exons 8 and 10 in the patient’s extracranial metastatic meningioma. The findings suggested that EXO1 homozygous deletion may be associated with suppression of hydroxyurea sensitivity in anaplastic meningiomas. Hydroxyurea should be a justified therapeutic adaptation in cases of anaplastic meningioma without EOX1 homozygous deletion.

Original languageEnglish
Pages (from-to)18618-18625
Number of pages8
JournalInternational Journal of Clinical and Experimental Medicine
Volume9
Issue number9
Publication statusPublished - 2016 Sep 30
Externally publishedYes

Fingerprint

Chemotherapy
Hydroxyurea
Meningioma
Neoplasm Metastasis
Tumors
Radiotherapy
Liver
Magnetic resonance imaging
Surgery
Brain
Drug Therapy
Lung
Cell growth
Exons
Cells
Apoptosis
Radiation
Magnetic Resonance Imaging
Occipital Lobe
Neoplasms

Keywords

  • Anaplastic meningioma
  • EXO1
  • Hydroxyurea

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yoshimura, S., Ohta, T., Makita, K., Yamamuro, S., Ochai, Y., Sumi, K., ... Tanaka, S. (2016). EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases. International Journal of Clinical and Experimental Medicine, 9(9), 18618-18625.

EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases. / Yoshimura, Sodai; Ohta, Takashi; Makita, Kotaro; Yamamuro, Shun; Ochai, Yushi; Sumi, Koichiro; Shijo, Katsunori; Yoshino, Atsuo; Homma, Taku; Sugitani, Masahiko; Yuzawa, Sayaka; Nishihara, Hiroshi; Tanaka, Sinya.

In: International Journal of Clinical and Experimental Medicine, Vol. 9, No. 9, 30.09.2016, p. 18618-18625.

Research output: Contribution to journalArticle

Yoshimura, S, Ohta, T, Makita, K, Yamamuro, S, Ochai, Y, Sumi, K, Shijo, K, Yoshino, A, Homma, T, Sugitani, M, Yuzawa, S, Nishihara, H & Tanaka, S 2016, 'EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases', International Journal of Clinical and Experimental Medicine, vol. 9, no. 9, pp. 18618-18625.
Yoshimura, Sodai ; Ohta, Takashi ; Makita, Kotaro ; Yamamuro, Shun ; Ochai, Yushi ; Sumi, Koichiro ; Shijo, Katsunori ; Yoshino, Atsuo ; Homma, Taku ; Sugitani, Masahiko ; Yuzawa, Sayaka ; Nishihara, Hiroshi ; Tanaka, Sinya. / EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases. In: International Journal of Clinical and Experimental Medicine. 2016 ; Vol. 9, No. 9. pp. 18618-18625.
@article{26a257c84b5e44ed92df0a4ff45e5f1b,
title = "EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases",
abstract = "Background: Anaplastic meningioma is exceedingly rare, and its clinicopathological features are distinctive. Distant meningioma metastases have previously been reported to be very rare. The most common site of metastasis is the lung, which accounts for 61{\%} of all meningioma metastases. The standard therapy for meningiomas is total resection and/or radiation therapy. Case Report: A 71-year-old man was admitted with headache and left hemiparesis. Magnetic resonance imaging (MRI) revealed mass lesions at the right frontal convexity and left occipital lobe. Following surgery, pathological examinations demonstrated an anaplastic meningioma. At 3 months after the operation and radiation therapy, lung tumor was removed. The pathological findings for the lung tumor resembled those of the brain tumor. A diagnosis of metastatic lung tumor from anaplastic meningioma was made. At 2 months after the lung surgery, MRI disclosed focal recurrence in the frontal convexity area and progression into the cavernous sinus. Abdominal CT detected a new metastatic lesion in the patient’s liver. He underwent adjuvant reirradiation consisting of whole brain radiotherapy. In addition, he received chemotherapy using angiogenesis receptor (bevacizumab). Chemotherapy with hydroxyurea was initiated after 2 courses of the bevacizumab chemotherapy, because his hepatic lesion had become more aggressive. The intracranial mass was reduced by 50{\%} at 8 weeks after initiation of the hydroxyurea chemotherapy. However, there was no significant effect on the liver and lung metastases. Analysis and Conclusion: Extracranial metastases have been estimated to occur in only 0.1{\%} of all meningiomas and most often in association with anaplastic meningiomas. While total resection and/ or radiation treatment provide the standard therapy for meningiomas, use of chemotherapy against meningiomas has been limited to distant metastases or based on out of surgical criteria. Several reports have demonstrated that hydroxyurea provides on effective chemotherapy for meningiomas including grade I cases. Hydroxyurea halts meningioma cell growth through arrest of the S-phase of the cell cycle, thus inducing apoptosis. Our analysis revealed EXO1 homozygous deletion at exons 8 and 10 in the patient’s extracranial metastatic meningioma. The findings suggested that EXO1 homozygous deletion may be associated with suppression of hydroxyurea sensitivity in anaplastic meningiomas. Hydroxyurea should be a justified therapeutic adaptation in cases of anaplastic meningioma without EOX1 homozygous deletion.",
keywords = "Anaplastic meningioma, EXO1, Hydroxyurea",
author = "Sodai Yoshimura and Takashi Ohta and Kotaro Makita and Shun Yamamuro and Yushi Ochai and Koichiro Sumi and Katsunori Shijo and Atsuo Yoshino and Taku Homma and Masahiko Sugitani and Sayaka Yuzawa and Hiroshi Nishihara and Sinya Tanaka",
year = "2016",
month = "9",
day = "30",
language = "English",
volume = "9",
pages = "18618--18625",
journal = "International Journal of Clinical and Experimental Medicine",
issn = "1940-5901",
publisher = "e-Century Publishing Corporation",
number = "9",

}

TY - JOUR

T1 - EXO1 homozygous deletion suppresses the hydroxyurea sensitivity in anaplastic meningioma with extracranial metastases

AU - Yoshimura, Sodai

AU - Ohta, Takashi

AU - Makita, Kotaro

AU - Yamamuro, Shun

AU - Ochai, Yushi

AU - Sumi, Koichiro

AU - Shijo, Katsunori

AU - Yoshino, Atsuo

AU - Homma, Taku

AU - Sugitani, Masahiko

AU - Yuzawa, Sayaka

AU - Nishihara, Hiroshi

AU - Tanaka, Sinya

PY - 2016/9/30

Y1 - 2016/9/30

N2 - Background: Anaplastic meningioma is exceedingly rare, and its clinicopathological features are distinctive. Distant meningioma metastases have previously been reported to be very rare. The most common site of metastasis is the lung, which accounts for 61% of all meningioma metastases. The standard therapy for meningiomas is total resection and/or radiation therapy. Case Report: A 71-year-old man was admitted with headache and left hemiparesis. Magnetic resonance imaging (MRI) revealed mass lesions at the right frontal convexity and left occipital lobe. Following surgery, pathological examinations demonstrated an anaplastic meningioma. At 3 months after the operation and radiation therapy, lung tumor was removed. The pathological findings for the lung tumor resembled those of the brain tumor. A diagnosis of metastatic lung tumor from anaplastic meningioma was made. At 2 months after the lung surgery, MRI disclosed focal recurrence in the frontal convexity area and progression into the cavernous sinus. Abdominal CT detected a new metastatic lesion in the patient’s liver. He underwent adjuvant reirradiation consisting of whole brain radiotherapy. In addition, he received chemotherapy using angiogenesis receptor (bevacizumab). Chemotherapy with hydroxyurea was initiated after 2 courses of the bevacizumab chemotherapy, because his hepatic lesion had become more aggressive. The intracranial mass was reduced by 50% at 8 weeks after initiation of the hydroxyurea chemotherapy. However, there was no significant effect on the liver and lung metastases. Analysis and Conclusion: Extracranial metastases have been estimated to occur in only 0.1% of all meningiomas and most often in association with anaplastic meningiomas. While total resection and/ or radiation treatment provide the standard therapy for meningiomas, use of chemotherapy against meningiomas has been limited to distant metastases or based on out of surgical criteria. Several reports have demonstrated that hydroxyurea provides on effective chemotherapy for meningiomas including grade I cases. Hydroxyurea halts meningioma cell growth through arrest of the S-phase of the cell cycle, thus inducing apoptosis. Our analysis revealed EXO1 homozygous deletion at exons 8 and 10 in the patient’s extracranial metastatic meningioma. The findings suggested that EXO1 homozygous deletion may be associated with suppression of hydroxyurea sensitivity in anaplastic meningiomas. Hydroxyurea should be a justified therapeutic adaptation in cases of anaplastic meningioma without EOX1 homozygous deletion.

AB - Background: Anaplastic meningioma is exceedingly rare, and its clinicopathological features are distinctive. Distant meningioma metastases have previously been reported to be very rare. The most common site of metastasis is the lung, which accounts for 61% of all meningioma metastases. The standard therapy for meningiomas is total resection and/or radiation therapy. Case Report: A 71-year-old man was admitted with headache and left hemiparesis. Magnetic resonance imaging (MRI) revealed mass lesions at the right frontal convexity and left occipital lobe. Following surgery, pathological examinations demonstrated an anaplastic meningioma. At 3 months after the operation and radiation therapy, lung tumor was removed. The pathological findings for the lung tumor resembled those of the brain tumor. A diagnosis of metastatic lung tumor from anaplastic meningioma was made. At 2 months after the lung surgery, MRI disclosed focal recurrence in the frontal convexity area and progression into the cavernous sinus. Abdominal CT detected a new metastatic lesion in the patient’s liver. He underwent adjuvant reirradiation consisting of whole brain radiotherapy. In addition, he received chemotherapy using angiogenesis receptor (bevacizumab). Chemotherapy with hydroxyurea was initiated after 2 courses of the bevacizumab chemotherapy, because his hepatic lesion had become more aggressive. The intracranial mass was reduced by 50% at 8 weeks after initiation of the hydroxyurea chemotherapy. However, there was no significant effect on the liver and lung metastases. Analysis and Conclusion: Extracranial metastases have been estimated to occur in only 0.1% of all meningiomas and most often in association with anaplastic meningiomas. While total resection and/ or radiation treatment provide the standard therapy for meningiomas, use of chemotherapy against meningiomas has been limited to distant metastases or based on out of surgical criteria. Several reports have demonstrated that hydroxyurea provides on effective chemotherapy for meningiomas including grade I cases. Hydroxyurea halts meningioma cell growth through arrest of the S-phase of the cell cycle, thus inducing apoptosis. Our analysis revealed EXO1 homozygous deletion at exons 8 and 10 in the patient’s extracranial metastatic meningioma. The findings suggested that EXO1 homozygous deletion may be associated with suppression of hydroxyurea sensitivity in anaplastic meningiomas. Hydroxyurea should be a justified therapeutic adaptation in cases of anaplastic meningioma without EOX1 homozygous deletion.

KW - Anaplastic meningioma

KW - EXO1

KW - Hydroxyurea

UR - http://www.scopus.com/inward/record.url?scp=84989193459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989193459&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84989193459

VL - 9

SP - 18618

EP - 18625

JO - International Journal of Clinical and Experimental Medicine

JF - International Journal of Clinical and Experimental Medicine

SN - 1940-5901

IS - 9

ER -